Prostaglandin F(2alpha) regulation of the bovine corpus luteum endothelin system during the early and midluteal phase.
Recent evidence in the cow suggests that endothelin-1 (ET-1) plays a role during prostaglandin (PG) F(2alpha)-induced luteal regression. We have examined the effects of treatment with PGF(2alpha) during the early and midluteal phases on three components of the endothelin system: endothelin-converting enzyme-1 (ECE-1), ET type A receptor (ET(A)), and ET-1 in the bovine corpus luteum (CL). Cyclic beef cows were injected (0 h) on Day 4 or 10 with either saline or the PGF(2alpha) analogue Lutalyse (15 mg). The CL were collected at 2 (n = 11), 10 (n = 23), 24 (n = 15), or 48 h (n = 12) after treatment. The cows in which CL were removed after 10 h comprised of two experimental groups. The first group (n = 11) received one injection; the second group (n = 12) received two injections, one at 0 h and one at 8 h. The cows in which CL were collected after 24 and 48 h received one injection every 8 h. Semiquantitative reverse transcriptase-polymerase chain reaction was used to evaluate the mRNA encoding ECE-1, ET(A), and ET-1. The ECE-1 and ET(A) proteins were evaluated by semiquantitative Western blot analysis. The ET-1 was the most likely component of the endothelin system target for PGF(2alpha) regulation during the midluteal phase. The ET(A) and ECE-1 genes were constitutively expressed in the Day 4 and Day 10 CL. A practical application of this observation is that it may be possible to target the ET-1 gene as a way to manipulate the luteolytic action of PGF(2alpha).
Wright
M F
MF
Department of Biology, West Virginia University, Morgantown, West Virginia 26506-6057, USA.
Sayre
B
B
Keith Inskeep
E K
EK
Flores
J A
JA
D000199:Actins / Q000235:genetics; D000818:Animals; D016282:Aspartic Acid Endopeptidases / Q000032:analysis / Q000235:genetics; D015153:Blotting, Western; D002417:Cattle / Q000502:physiology*; D003338:Corpus Luteum / Q000737:chemistry / Q000378:metabolism*; D015237:Dinoprost / Q000031:analogs & derivatives / Q000494:pharmacology*; D019332:Endothelin-1 / Q000032:analysis / Q000235:genetics; D000072396:Endothelin-Converting Enzymes; D016232:Endothelins / Q000235:genetics*; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects*; D008183:Luteal Phase; D008666:Metalloendopeptidases; D012333:RNA, Messenger / Q000032:analysis; D044022:Receptor, Endothelin A; D017466:Receptors, Endothelin / Q000032:analysis / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction
D000199:Actins; D019332:Endothelin-1; D016232:Endothelins; D012333:RNA, Messenger; D044022:Receptor, Endothelin A; D017466:Receptors, Endothelin; D015237:Dinoprost; C010714:dinoprost tromethamine; D016282:Aspartic Acid Endopeptidases; D008666:Metalloendopeptidases; D000072396:Endothelin-Converting Enzymes